• EN

Jacobio Pharma to Announce Two Oral Presentation at 2024 ASCO

Apr 26, 2024

Beijing, Shanghai, Chicago, Apr 26, 2024—Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced the acceptance of two abstracts for oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 held in Chicago, May 31 to June 4, 2024.  The updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) will be presented in the oral abstract session of Developmental Therapeutics on June 1, 2024, and the topline results of the pivotal phase 2 single-arm study of glecirasib in NSCLC will be discussed in the Education Session.  

The details are as follows:

A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation
Abstract #:468214
Time:April 30, 2024, 12:00-13:00 PM (GMT-5)
Session Type:Online Oral Presentation—ASCO Plenary Series Program
Presenter:Prof. Yuankai Shi

Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors
Abstract #:3008
Time:June 1, 2024, 15:00 PM (GMT-5)
Session Type: Oral Abstract Session
Clinical Trial Registration Number: NCT05288205

Updates on Abstract 468214: A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation
Time:June 1, 2024, 13:00 PM (GMT-5)
Session Type: Education Session

Dr. Andrea Wang-Gillam, Chief Medical Officer and Global Head of R&D of Jacobio Pharma, said: “We are honored to share the results of two studies in oral sessions at 2024 ASCO. Jacobio is one of leading companies deeply invested in the development of RAS pathway inhibitors. JAB-3312 is the first SHP2 inhibitor entered the phase III clinical trial, and the pivotal trial design of combining KRAS G12C inhibitor and SHP2 inhibitor was based on the   preliminary safety and response results presented at 2023 EMSO and long-term safety and duration data at 2024 ASCO. Additionally, the results from the pivotal phase II single agent glecirasib in non-small cell lung cancer will be presented at ASCO plenary Series Program on April 30 and further updated in the Educational Session on June 1, 2024.  

The 2024 ASCO Annual Meeting will be held in Chicago, Illinois, U.S. from May 31 to June 4. For more information, please visit the official website of the ASCO: https://conferences.asco.org/am/attend.

About Glecirasib
Glecirasib is a KRAS G12C inhibitor developed by Jacobio. A number of Phase I/II clinical trials of glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include a pivotal clinical trial in NSCLC in China; a monotherapy study for STK11 co-mutated NSCLC in the front-line setting, and combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with Cetuximab in colorectal cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China.

About JAB-3312
JAB-3312 is a highly selective SHP2 allosteric inhibitor with best-in-class potential. Jacobio is currently conducting clinical trials of JAB-3312 in monotherapy and combination therapies with glecirasib and other agents in China, the United States and Europe. The phase III study in combination with KRAS G12C inhibitor Glecirasib has been approved by China CDE in Feb 2024. 

About Jacobio

Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.